Phostphatide precursors and cofactors improved memory in Mild Alzheimer’s disease (AD)
......................................................................................................................................................................................................................................................................................................................................................................................................
According to Alzheimer’s and Dementia, Volume 6, Issue 1, January 2010, Pages 1-10.e1; conclude that supplementation with a medical food including Phostphatide precursors and cofactors for 12 weeks improved memory (delayed verbal recall) in mild AD patients.
Alzheimer’s disease is the leading cause of dementia characterized by accumulation of beta-amyloid plaques, neurofibrillary tangles, and synaptic loss, ultimately leading to cerebral atrophy and enlargement of ventricle leads to the clinical feature of AD likes memory impairment, language deterioration and executive and visuospatial dysfunction. Only central cholinergic or glutaminergic neurotransmission, provide only symptomatic relief.
New approaches to prevent and treat AD are needed. Because the cognitive disturbances of AD best correlate with loss of hippocampal and cortical synapses. Preclinical studies indicate that such an effect can be induced by co-administration of rate-limiting precursor for membrane Phostphatide synthesis, such as nucleotide uridine, omega-3 polyunsaturated fatty acids and choline. These nutrients synergistically increase brain levels of Phostphatide molecules that comprise the bulk of synaptic membranes and brain levels of specific synaptic proteins, suggesting that they also increase synapse formation moreover these nutrition produces major increase in hippocampal dendritic spines, the anatomical precursor of and surrogate marker of new synapse.
For this, A total of 225 drug-naïve AD patients participated in this randomized, double-blind controlled trial. Patients were randomized to active product, Souvenaid, or a control drink, taken once-daily for 12 weeks. Primary outcome measures were the delayed verbal recall task of the Wechsler Memory Scale–revised, and the 13-item modified Alzheimer’s disease Assessment Scale–cognitive subscale at week 12.
Researcher found result at 12 weeks, significant improvement in the delayed verbal recall task was noted in the active group compared with control (P = .021). Modified Alzheimer’s Disease Assessment Scale–cognitive subscale and other outcome scores (e.g., Clinician Interview Based Impression of Change plus Caregiver Input, 12-item Neuropsychiatric Inventory, Alzheimer’s disease Co-operative Study–Activities of Daily Living, Quality of Life in Alzheimer’s Disease) were unchanged. The control group neither deteriorated nor improved. Compliance was excellent (95%) and the product was well tolerated.
Source: sciencedirect.com
Filed Under: Research
Loading ...
